Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

被引：0
|
作者：
Hochster, H. [1 ]
Catalano, Paul J. [2 ]
O'Dwyer, Peter J. [3 ]
Mitchell, Edith P. [4 ]
Cohen, Deirdre Jill [5 ,6 ]
Faller, Bryan Andrew [7 ]
Kortmansky, Jeremy S. [8 ]
Kircher, Sheetal Mehta [9 ]
Lacy, Jill [10 ]
Lenz, Heinz-Josef [11 ]
Verma, Udit N. [12 ]
Benson, Al Bowen, III [13 ]
机构：
[1] Rutgers Canc Inst, New Brunswick, NJ USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[5] NYU Perlmutter Canc Ctr, New York, NY USA
[6] ECOG ACRIN, New York, NY USA
[7] Midwest Hem & Onc Assoc, Clayton, MO USA
[8] Med Oncol & Hematol, Hamden, CT USA
[9] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[10] Yale Univ, Smilow Canc Hosp, New Haven, CT USA
[11] Univ Southern Calif, Los Angeles, CA USA
[12] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[13] Northwestern Med, Chicago, IL USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 030
引用
收藏
页数：1
相关论文
共 38 条
  • [31] Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer
    Horgan, A. M.
    Shepherd, F. A.
    Bradbury, P. A.
    Ng, R.
    Leighl, N. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.
    Eng, Cathy
    Hart, Lowell L.
    Severtsev, Aleksey
    Gladkov, Oleg
    Mueller, Lothar
    Kopp, Mikhail V.
    Vladimirov, Vladimir Ivanovich
    Langdon, Robert M.
    Kotiv, Bogdan
    Barni, Sandro
    Hsu, Ching
    Bolotin, Ellen
    Von Roemeling, Reinhard
    Schwartz, Brian E.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2+/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49
    Pernot, Simon
    Pellerin, Olivier
    Mineur, Laurent
    Monterymard, Carole
    Smith, Denis
    Lapuyade, Bruno
    Gallois, Claire
    Tougeron, David
    Thirot-Bidault, Anne
    Audemar, Franck
    Simon, Mireille
    Lecaille, Cedric
    Louafi, Sami
    Lepage, Come
    Ducreux, Michel
    Taieb, Julien
    Akouz, Faiza Khemissa
    De Baere, Thierry
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (03) : 324 - 330
  • [34] Two-year follow up results of a population-based prospective case control study of 143 stage IV colorectal cancer (CRC) patients treated with 2nd line irinotecan (iri) outside of clinical trial.
    Lang, I
    Hitre, E
    Horvath, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
  • [35] North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma
    McWilliams, Robert R.
    Foster, Nathan R.
    Mahoney, Michelle R.
    Smyrk, Thomas C.
    Murray, Joseph A.
    Ames, Matthew M.
    Horvath, L. Elise
    Schneider, Daniel J.
    Hobday, Timothy J.
    Jatoi, Aminah
    Meyers, Jeffrey P.
    Goetz, Matthew P.
    CANCER, 2017, 123 (18) : 3494 - 3501
  • [36] Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy.
    Rowland, KM
    Pitot, HC
    Sargent, DJ
    Philip, PA
    Mitchell, EP
    Mailliard, JA
    Goldberg, RM
    Alberts, SR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 250S - 250S
  • [37] RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp)
    Tabernero, Josep
    Cohn, Allen Lee
    Obermannova, Radka
    Bodoky, Gyorgy
    Garcia-Carbonero, Rocio
    Ciuleanu, Tudor-Eliade
    Portnoy, David Craig
    Van Cutsem, Eric
    Grothey, Axel
    Prausova, Jana
    Garcia-Alfonso, Pilar
    Yamazaki, Kentaro
    Clingan, Philip R.
    Zagonel, Vittorina
    Kim, Tae Won
    Simms, Lorinda
    Chang, Shao-Chun
    Nasroulah, Federico
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).
    Grothey, Axel
    Tabernero, Josep
    Rougier, Philippe
    Ballal, Shaila
    Crane, Heidi
    Rutstein, Mark D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
1234